Finanzen von Regulus Therapeutics Inc (RGLS)RGLSRegulus Therapeutics Inc

Evaluating the bottom line, Regulus Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.82%, provide a clear picture of how effectively RGLS converts its operational activities into shareholder value.

In the context of the broader market, RGLS competes directly with industry leaders such as AMLX and KALV. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, RGLS's gross margin of N/A stands against AMLX's N/A and KALV's 92.44%. Such benchmarking helps identify whether Regulus Therapeutics Inc is trading at a premium or discount relative to its financial performance.